Phase ? Study of Pegylated Liposomal Doxorubicin?PLD?Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HER2 Positive Breast Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03933319
- Collaborators
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Investigators
- Principal Investigator: peng yuan Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Get Well Soon